Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). Get the full story at our sister site, Drug Delivery Business News.
Pear Therapeutics
Pear Therapeutics reports positive real-world data for chronic insomnia treatment
Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT). Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up. Get the full story at our sister site, […]
Digital therapeutics open up new opportunities in medicine
A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently. “We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition […]
FDA grants STeP designation for Pear Therapeutics’ neurobehavioral digital therapeutic
Pear Therapeutics (Nasdaq:PEAR) announced today that it received STeP designation from the FDA for its Pear-010 product candidate. Boston-based Pear Therapeutics designed its Pear-010 prescription digital therapeutic (PDT) candidate to provide a neurobehavioral intervention (virtual reality-delivered pain reduction) to patients 18 and older with acute postoperative and acute postprocedural pain. The company said in a […]
Pear Therapeutics launches program to offer digital therapeutics through telehealth platforms
Pear Therapeutics (Nasdaq:PEAR) announced today that it launched a program to offer digital therapeutic users access to a telehealth provider. Boston-based Pear’s program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool,” as well as in-person care options. Get the […]
Pear Therapeutics posts massive Q4 revenue uptick as product sales increase
Pear Therapeutics (Nasdaq:PEAR) missed Wall Street’s fourth-quarter revenue projections despite a major year-over-year increase in sales. The Boston-based prescription digital therapeutic (PDT) developer posted profits of $18.8 million, or 13¢ per share, on sales of $1.2 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain from losses of nearly $48 […]
Pear Therapeutics joins Epic App Orchard to enable monitoring of its digital therapeutics
Pear Therapeutics (Nasdaq:PEAR) announced today that its PearConnect platform is now available in the Epic App Orchard Gallery. By making PearConnect available to healthcare providers through the Epic App Orchard Gallery, the providers who implement the application will be able to access PearConnect within Epic’s leading electronic health record (EHR) platform, allowing them to monitor patients […]
Pear Therapeutics to develop digital therapeutic for sleep/wake disorder in Japan
Pear Therapeutics (Nasdaq:PEAR) announced today that it entered an agreement to develop a Japanese-language digital therapeutic. Boston-based Pear struck a deal with SoftBank, a Japan-based communication and information technology service provider, to develop the digital therapeutic for the treatment of sleep/wake disorders on the Japanese market. Get the full story at our sister site, Drug Delivery […]
Pear Therapeutics says new data backs its prescription digital therapeutic for insomnia
Pear Therapeutics (Nasdaq:PEAR) today announced data from two studies that highlight the effectiveness of its chronic insomnia treatment. Boston-based Pear Therapeutics designed its Somryst prescription digital therapeutic (PDT) to address the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), training the body to sleep. The nine-week PDT can be used on […]
Pear Therapeutics advances in efforts to get CMS to cover prescription digital therapeutics
Pear Therapeutics (NSDQ:PEAR) announced that the Centers for Medicare & Medicaid Services (CMS) established new coding relevant to its prescription digital therapeutics (PDTs). CMS established a new Level II Healthcare Common Procedure Coding System (HCPCS) code to describe prescription digital behavioral therapy — FDA-cleared — per course of treatment, which extends to PDTs including Pear’s reSET, […]
Pear Therapeutics closes SPAC merger, lists on Nasdaq
Pear Therapeutics today began trading on the Nasdaq market following the completion of a previously announced merger at the end of last week. Boston-based Pear confirmed in June that it would go public by merging Thimble Point Acquisition Corp., a special purpose acquisition company (SPAC). Following approval from Thimble Point’s stockholders at the end of […]